Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML).
| I N T R O D U C T I O N
Acute myeloid leukemia (AML) is a highly heterogeneous disease, mainly experienced by older adults. 1 Median age at a diagnosis is 67
and approximately 30% of the cases are diagnosed in patients older than 75 years. [2] [3] [4] Currently, treatment results of AML in patients aged 60 or older remain unsatisfactory. The treatment strategy for each patient is based on performance status, comorbidities, and diseaserelated prognostic factors. 5 Patient's survival depends on achieving complete remission (CR) and preventing a relapse. Recognition of AML in patients older than 60 years has resulted in a medical dilemma concerning finding the best possible implementation of a correct mode of the treatment, taking into account risk factors.
The most commonly used standard of the induction treatment, that is, DA (3 1 7), consists of 3 days of daunorubicin (DNR) with 7 days of cytarabine (Ara-C). It is used in clinical practice in all age groups of AML patients. 6 A previous trial by the Polish Adult Leukemia Group (PALG) has demonstrated that a combination of cladribine (2-CdA) with DNR and Ara-C resulted in a significantly increased CR rate after the first induction treatment course in AML 60 years of age. Particularly patients older than 40 years benefited from addition of 2-CdA to the standard treatment (CR rate 45% vs. 60%; P < .05). 7 A combination of 2-CdA, Ara-C, and anthracycline has been tested in a study on untreated, elderly AML patients and has shown no additional toxicity. 8 Addition of 2-CdA to an intensive therapy has been also associated with a high response rate and good tolerance in relapse and refractory AML patients. 9, 10 Such promising results, along with acceptable toxicity of the DAC regimen, prompted this study: a randomized multicenter phase II trial comparing the DAC with standard DA regimen in newly diagnosed, elderly AML patients eligible for intensive chemotherapy.
| MATERIALS A ND METHODS

| Study group
The patients were considered eligible if they fulfilled the following criteria: AML diagnosis established according to the WHO criterion, age over 60 but less than 80, Eastern Cooperative Oncology Group (ECOG) performance status 2, and lack of severe comorbidities (Charlson comorbidity index 0-2). 1, 11 Patients with acute promyelocytic leukemia were excluded from the study.
One hundred and seventy-one newly diagnosed de novo or secondary AML patients treated in 17 Hematology Departments in Poland between May 2004 and September 2010 were enrolled into the study.
The primary end point was to achieve CR after the first induction course. Toxicity profile, overall survival (OS), and disease free survival (DFS) were secondary endpoints.
Karyotypes were analyzed according to the International System The study was approved by the bioethical committees of the participating institutions and conducted in accordance with the Declaration of Helsinki. All the participants gave their written informed consent to take part in the study.
| Treatment regimens
The patients were screened at each PALG center. Following verification of eligibility criteria, they were centrally randomized to one of two Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. 14, 15 In brief, CR was defined as the presence of less than 5% BM blasts with a neutrophil count higher than 1.0 g/L, a platelet count higher than 100 g/L, and no extramedullary disease. PR was established as either 5%-25% BM blasts, a 50% or more decrease in BM blasts, or BM blasts <5% but with the presence of Auer rods. No response (NR) was established in the case of patients who did not fulfill the above-mentioned criteria. Early death (ED) was defined as a death from any cause within 4 weeks after the induction therapy and was considered as the treatment failure. DFS was calculated from the first day of CR until the documentation of relapse. OS was calculated from the time of diagnosis until death.
| Statistical analysis
The size of the study was based on the power to detect an increase of the CR rate from 30% in the DA group to 45% for in the DAC group. Kaplan-Meier estimates of survival were calculated and compared using the log-rank test.
The effect of the type of induction was analyzed in the whole group and in the subgroups stratified by age and karyotype. The subgroup analyses were predefined although the cut-off value for age was determined post hoc based on the patients' characteristics. Effects heterogeneity was verified using the Cochrane Q test. P values < .05 were considered significant.
| R E S U LTS
| Patients' characteristics
A total of 171 patients were included in the study and were randomly assigned to one of the treatment arms (DA, 86; DAC, 85). One patient in the DA arm died before the treatment implementation due to hemorrhage to the central nervous system. In the DAC arm, three patients died due to influenza in epidemic time, one died due to gastrointestinal tract hemorrhage, and one patient withdrew his informed consent before the treatment implementation. The overall, 165 patients were available for the further analysis (DA, 85; DAC 80). Characteristic of the study patients is presented in Table I 
| Response to induction treatment
Of the whole group, a CR was achieved after a single course of induction in 64 patients (39%). Four of 19 patients (12%) with PR received the second repeated course of the induction, and all achieved CR, leading to an overall CR rate of 41%. Fifteen patients were excluded from the second induction course due to a severe infection or significant worsening of performance status. The CR rate after the first induction course in the DAC arm and the DA arm was 44% vs. 34%, respectively (P 5 .19). DAC induction was associated with less frequent resistance to the treatment compared with the DA arm (23% vs. 36%). The incidence of early death in the DAC and DA arms was 23% vs. 17%, respectively ( Table 2 ). The subgroup analysis revealed that the patients younger than 65 significantly benefited from addition of cladribine to the standard treatment (CR rate 51% vs. 29%; P 5 .02; respectively); however, this observation did not affect the patients older than 65 years (Table 2 ). In the younger patients, even higher CR rates were observed in the DAC arm in the good and intermediate cytogenetic risk groups (69% vs. 21% in the DA arm P 5 .0032, respectively) ( Table 3 ).
| Overall survival
The median time of follow-up was 6.4 (0.03-61.3) months. The median OS time for the whole group was 8.6 months. No significant difference in OS was observed between the DA and DAC regimens.
The median OS was 9.1 months (95% CI 5.22-13.107) in the DA arm 
| DISCUSSION
AML is a heterogeneous disease progressing along with age, risk factors based on karyotype, molecular markers, and patient's characteristics. Several studies have attempted to determine which treatment strategy may improve outcomes in specific subgroups of patients. One of the modern options is supplementation of chemotherapy together with small active molecules for repairing single cell pathways. However, this strategy is based on detailed molecular diagnostics, which requires additional time before initiation of treatment and the use of an available molecular laboratory. Time before commencement of a therapy should be as short as possible, ideally less than 7 days after a diagnosis. 5 Therefore, targeted treatment may play a more important role during consolidation therapy, when a major reduction of leukemic burden is achieved. The search for the most suitable all-purpose induction option for elderly AML patients who are fit for intensive chemotherapy has been a challenge for many hematologists. The CR rate after the first course of induction in the DAC group was 44%, compared to 34% in the DA group. The further analysis revealed a higher CR rate in the DAC arm than in the DA arm among the patients aged 60-65 (51% vs. 29%). This difference was even higher in the good and intermediate karyotype risk groups (69% vs. 21%). Addition of cladribine resulted in decreased leukemia resistance, while early mortality remained similar in both groups. In addition, both hematologic and nonhematologic toxicity was comparable among the treatment arms, indicating that addition of purine analogs did not impair tolerance of the treatment. 7, 9, 10, 16 A previous PALG study performed on an AML population aged under 60 has examined addition of purine analogs to the standard induction treatment (3 1 7) . 6, 16 Patients in that study were randomized in AML patients <60 years of age were analyzed. CR rate after one induction cycle was 67%, and this regimen was also well tolerated. 17 Based on trials that covered younger AML patients, addition of cladribine as a third drug into the induction course is an effective option. All patients were given a second cycle of Ara-C 1000 mg/m 2 twice a day for 6 days. The CR rate after the first cycle was 35% in the standard arm (DA-45), compared to 52% in the escalated-dose group (DA-90). After the second cycle of Ara-C, the CR rate was 54% in the standard treatment group compared to 64% in the escalating group.
In this study, the CR rate in the DA arm was comparable to that observed by Lowenberg in DA-45. However, in the escalated DA-90 arm, the CR rate was higher than in our DAC arm (52% vs. 44%, respectively). This observation could be attributed to the differences between the characteristics of the AML populations and the higher incidence of secondary AML in our DAC population (32% in DAC vs.
23% in DA-90).
In 23 The CR rate after a single course of chemotherapy was 57% in the whole cohort: 54% in DNR arm vs. 59% in IDA arm, differences were statistically insignificant. The CR rate in this trial was a little higher than that observed in our study. This difference could be related to the higher frequency of adverse risk factors (adverse cytogenetic, secondary AML) in our population and a lower dose of Ara-C used in our induction regimens , days 1-5. CR rate was 79%. 27 Addition of purine analog as a third drug to the standard treatment seems to be an interesting option for all AML patients improving response to the induction chemotherapy.
In this study, OS was 9.1 months for the DA arm and 8.6 months for the DAC arm (P 5 .64). Survival assessment in the subgroups according to a patient's age (65 and >65 years), cytogenetic risk and induction treatment indicated better OS scores in the DAC arm than in the DA arm for younger patients (<65 years) with good-and intermediate-risk karyotypes (P 5 .02). As no difference could be demonstrated with respect to DFS, the observed survival advantage can probably be attributed to the improved CR rate.
Our results suggest that DAC induction in AML patients over the age of 60 is an active treatment with standard toxicity and may be a 
